Literature DB >> 22750953

Prostate cancer: new types of radiotherapy improve cancer outcome but at what cost?

Declan G Murphy1, Scott Williams2, Matthew R Cooperberg3.   

Abstract

New and very expensive forms of radiotherapy, such as intensity-modulated radiation therapy and proton therapy, have taken over the localized prostate cancer market. But is there enough evidence to justify their increased utilization and if so, how can we possibly afford them?

Entities:  

Mesh：

Year:  2012        PMID： 22750953     DOI： 10.1038/nrurol.2012.137

Source DB:  PubMed          Journal:  Nat Rev Urol        ISSN： 1759-4812            Impact factor:   14.432


  8 in total

1.  The Titanic and the Iceberg: prostate proton therapy and health care economics.

Authors:  Anthony L Zietman
Journal:  J Clin Oncol       Date:  2007-08-20       Impact factor: 44.544

2.  Should randomized clinical trials be required for proton radiotherapy?

Authors:  Michael Goitein; James D Cox
Journal:  J Clin Oncol       Date:  2008-01-10       Impact factor: 44.544

3.  Perioperative outcomes of robot-assisted radical prostatectomy compared with open radical prostatectomy: results from the nationwide inpatient sample.

Authors:  Quoc-Dien Trinh; Jesse Sammon; Maxine Sun; Praful Ravi; Khurshid R Ghani; Marco Bianchi; Wooju Jeong; Shahrokh F Shariat; Jens Hansen; Jan Schmitges; Claudio Jeldres; Craig G Rogers; James O Peabody; Francesco Montorsi; Mani Menon; Pierre I Karakiewicz
Journal:  Eur Urol       Date:  2011-12-22       Impact factor: 20.096

4.  Cost implications of the rapid adoption of newer technologies for treating prostate cancer.

Authors:  Paul L Nguyen; Xiangmei Gu; Stuart R Lipsitz; Toni K Choueiri; Wesley W Choi; Yin Lei; Karen E Hoffman; Jim C Hu
Journal:  J Clin Oncol       Date:  2011-03-14       Impact factor: 44.544

5.  Intensity-modulated radiation therapy, proton therapy, or conformal radiation therapy and morbidity and disease control in localized prostate cancer.

Authors:  Nathan C Sheets; Gregg H Goldin; Anne-Marie Meyer; Yang Wu; YunKyung Chang; Til Stürmer; Jordan A Holmes; Bryce B Reeve; Paul A Godley; William R Carpenter; Ronald C Chen
Journal:  JAMA       Date:  2012-04-18       Impact factor: 56.272

6.  Randomized trial comparing conventional-dose with high-dose conformal radiation therapy in early-stage adenocarcinoma of the prostate: long-term results from proton radiation oncology group/american college of radiology 95-09.

Authors:  Anthony L Zietman; Kyounghwa Bae; Jerry D Slater; William U Shipley; Jason A Efstathiou; John J Coen; David A Bush; Margie Lunt; Daphna Y Spiegel; Rafi Skowronski; B Rodney Jabola; Carl J Rossi
Journal:  J Clin Oncol       Date:  2010-02-01       Impact factor: 44.544

7.  Prostate cancer radiation dose response: results of the M. D. Anderson phase III randomized trial.

Authors:  Alan Pollack; Gunar K Zagars; George Starkschall; John A Antolak; J Jack Lee; Eugene Huang; Andrew C von Eschenbach; Deborah A Kuban; Isaac Rosen
Journal:  Int J Radiat Oncol Biol Phys       Date:  2002-08-01       Impact factor: 7.038

8.  Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial.

Authors:  David P Dearnaley; Matthew R Sydes; John D Graham; Edwin G Aird; David Bottomley; Richard A Cowan; Robert A Huddart; Chakiath C Jose; John Hl Matthews; Jeremy Millar; A Rollo Moore; Rachel C Morgan; J Martin Russell; Christopher D Scrase; Richard J Stephens; Isabel Syndikus; Mahesh K B Parmar
Journal:  Lancet Oncol       Date:  2007-06       Impact factor: 41.316
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.